953 related articles for article (PubMed ID: 28866036)
1. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study.
Alfonso F; Cuesta J; Pérez-Vizcayno MJ; García Del Blanco B; Rumoroso JR; Bosa F; Pérez de Prado A; Masotti M; Moreno R; Cequier A; Gutiérrez H; García Touchard A; López-Mínguez JR; Zueco J; Martí V; Velázquez M; Morís C; Bastante T; García-Guimaraes M; Rivero F; Fernández C;
JACC Cardiovasc Interv; 2017 Sep; 10(18):1841-1851. PubMed ID: 28866036
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; Otaegui I; Masotti M; Zueco J; Veláquez M; Sanchís J; García-Touchard A; Lázaro-García R; Moreu J; Bethencourt A; Cuesta J; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C;
JACC Cardiovasc Interv; 2016 Jun; 9(12):1246-1255. PubMed ID: 27339840
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
[TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
[TBL] [Abstract][Full Text] [Related]
5. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
[TBL] [Abstract][Full Text] [Related]
6. Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study).
Alfonso F; Cuesta J; Ojeda S; Camacho-Freire S; García Del Blanco B; Vaquerizo B; Zueco J; Trillo R; Mauri J; Velázquez M; Córdoba-Soriano JG; Serra A; Navarro F; Pan M; Díaz J; Otaegui I; Salvatella N; De la TorreHernandez JM; Val DD; Bastante T; Rivero F;
Am J Cardiol; 2022 Jan; 162():31-40. PubMed ID: 34903344
[TBL] [Abstract][Full Text] [Related]
7. Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study).
Moscarella E; Tanaka A; Ielasi A; Cortese B; Coscarelli S; De Angelis MC; Piraino D; Latib A; Grigis G; Bianchi R; Buccheri D; Calabrò P; Tespili M; Silva Orrego P; Colombo A; Varricchio A
Catheter Cardiovasc Interv; 2018 Oct; 92(4):668-677. PubMed ID: 29356269
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials).
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; Masotti M; López-Minguez JR; Iñiguez A; Zueco J; Velazquez M; Cequier A; Lázaro-García R; Martí V; Moris C; Urbano-Carrillo C; Bastante T; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C;
Am J Cardiol; 2016 Feb; 117(4):546-554. PubMed ID: 26725102
[TBL] [Abstract][Full Text] [Related]
9. Scoring balloon predilation before bioresorbable vascular scaffold implantation in patients with in-stent restenosis: the RIBS VI 'scoring' study.
Alfonso F; Cuesta J; García Del Blanco B; Bosa F; Pérez de Prado A; Masotti M; Trillo R; Rumoroso JR; Moreno R; Cequier A; Gutiérrez H; García Touchard A; López-Mínguez JR; Zueco J; Serra A; Velázquez M; Morís C; Bastante T; García-Guimaraes M; Rivero F; Fernández-Pérez C;
Coron Artery Dis; 2021 Mar; 32(2):96-104. PubMed ID: 32558692
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial.
Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García del Blanco B; García-Touchard A; López-Minguéz JR; Benedicto A; Masotti M; Zueco J; Iñiguez A; Velázquez M; Moreno R; Mainar V; Domínguez A; Pomar F; Melgares R; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
J Am Coll Cardiol; 2015 Jul; 66(1):23-33. PubMed ID: 26139054
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial.
Baan J; Claessen BE; Dijk KB; Vendrik J; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; de Winter RJ; Koch KT; Sjauw KD; Beijk MA; Vis MM; Wykrzykowska JJ; Piek JJ; Tijssen JGP; Henriques JPS
JACC Cardiovasc Interv; 2018 Feb; 11(3):275-283. PubMed ID: 29413242
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent Restenosis (from the RIBS IV and V Randomized Trials).
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Sabaté M; Zueco J; Melgares R; Hernández R; Moreno R; Domínguez A; Sanchís J; Moris C; Moreu J; Cequier A; Romaguera R; Rivero F; Cuesta J; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
Am J Cardiol; 2017 Apr; 119(7):983-990. PubMed ID: 28139220
[TBL] [Abstract][Full Text] [Related]
16. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
[TBL] [Abstract][Full Text] [Related]
17. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
[TBL] [Abstract][Full Text] [Related]
18. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
19. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
[TBL] [Abstract][Full Text] [Related]
20. Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials.
Elgendy IY; Mahmoud AN; Elgendy AY; Mojadidi MK; Elbadawi A; Eshtehardi P; Pérez-Vizcayno MJ; Wayangankar SA; Jneid H; David Anderson R; Alfonso F
Cardiovasc Revasc Med; 2019 Jul; 20(7):612-618. PubMed ID: 30126824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
